Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone.
Shimazaki J, Hanada K, Yagi Y, Yamagami J, Ishioka M, Shimmura S, Tsubota K
AI Summary
Comparing glaucoma drops, unoprostone had no adverse ocular surface effects, while timolol significantly impaired tear production and turnover, highlighting important differences for patient comfort and eye health.
Abstract
Aim
To study changes induced in ocular surface epithelia and the tear film by antiglaucomatous eyedrops. A beta blocker (0.5% timolol) and a novel prostaglandin F(2alpha) metabolite related drug (0.12% unoprostone) were examined in a prospective, randomised fashion.
Methods
40 patients were randomly assigned to use either 0. 5% timolol (timolol group) or 0.12% unoprostone eyedrops (unoprostone group) twice a day for 24 weeks. In addition to routine ocular examinations, corneal epithelial integrity (vital staining tests, tear film break up time (BUT), anterior fluorometry, specular microscopy) and tear function (Schirmer's test, cotton thread test, tear clearance test (TCT)) were examined before and after the treatment.
Results
Both eyedrops caused significant reduction in intraocular pressure from the baseline levels. No significant changes were noted in corneal integrity in both groups, except a decrease in BUT at 20 weeks in the timolol group. The timolol group demonstrated significant decreases in Schirmer's test, tear clearance test, and tear function index (Schirmer's test value multiplied by clearance test); however, no such changes were noted in the unoprostone group.
Conclusion
While unoprostone eyedrops caused no adverse effects on the corneal epithelial integrity and tear function, timolol caused significant impairments in tear production and turnover.
MeSH Terms
Shields Classification
Related Articles5
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes.
Cohort StudyEffect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial.
Randomized Controlled TrialMorning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing.
Randomized Controlled TrialCost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
ReviewThe clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.